Is a combined oral contraceptive containing norethindrone 1 milligram (mg) and estradiol 5 micrograms (µg) appropriate for an obese woman weighing 250 pounds (≈113 kg) with a BMI of about 35 kg/m², who is under 35 years old and has no additional cardiovascular risk factors?

Combined Oral Contraceptive (Norethindrone 1mg + Estradiol 5mcg) for Obese Women

For an obese woman under 35 years old with BMI ~35 kg/m² and no additional cardiovascular risk factors, combined hormonal contraception containing norethindrone and estradiol is appropriate, as the benefits outweigh the theoretical risks in this specific clinical scenario 1.

Key Recommendation Based on Guidelines

The French Society of Endocrinology guidelines explicitly state that for women under 35 years of age with no cardiovascular risk factors and a BMI of 30 kg/m² or more, the benefits of combined hormonal contraception outweigh the theoretical risks 1. This directly applies to your patient with BMI ~35 kg/m².

Critical Qualifying Factors

The appropriateness hinges on confirming:

• Age under 35 years ✓
• No additional cardiovascular risk factors ✓ (must verify: non-smoker, no hypertension, no diabetes, no thrombophilia, no personal history of VTE)
• Isolated obesity (obesity is the only risk factor present)

Understanding the Risks

Venous Thromboembolism (VTE) Risk

The evidence shows that obesity and combined oral contraceptives have an additive, not synergistic, effect on VTE risk 1:

• Obese women (BMI >30) have a baseline relative risk of VTE of 3.70 compared to normal-weight women 1
• Combined oral contraceptives increase VTE risk by 3-4 fold
• When combined, obese COC users have approximately 10 times the risk of non-obese non-users 2
• However, the absolute risk remains small in women under 35 years old 1

Arterial Events

Limited evidence exists for arterial events (MI, stroke) in obese women under 35 using COCs. One study found relative risk of 5.1 for MI in obese COC users, but these events are rare in women under 35 years of age 1.

Efficacy Considerations

Does Obesity Reduce Effectiveness?

The evidence is reassuring for oral contraceptives:

• Most high-quality studies show no clinically significant reduction in oral contraceptive effectiveness with obesity 3, 4, 5
• A 2016 study specifically examining an ultra-low-dose COC (norethindrone acetate 1mg + ethinyl estradiol 10mcg) found Pearl Indices of 2.49,2.32, and 1.89 for BMI <25-30, and >30 kg/m², respectively—showing no clinically important difference 3
• Current data provide no firm evidence that efficacy of combined hormonal contraception is lower in obese women who use it correctly 1

Important Caveat

There are almost no data on women with BMI above 35 kg/m² 1. Your patient at BMI ~35 is at the upper limit of available evidence.

Clinical Algorithm for Decision-Making

Step 1: Screen for Absolute Contraindications

Verify absence of:

• Smoking (any amount if age >35; heavy smoking if age <35)
• Personal history of VTE or pulmonary embolism
• Known thrombophilia
• Hypertension
• Diabetes with vascular complications
• Migraine with aura
• Current or history of breast cancer

Step 2: If No Contraindications Present

• Prescribe the combined oral contraceptive (norethindrone 1mg + estradiol 5mcg)
• Counsel on VTE warning signs (leg pain/swelling, chest pain, shortness of breath)
• Emphasize perfect use to maximize efficacy
• Consider weight loss counseling as adjunct

Step 3: Alternative Options to Discuss

If patient or provider has concerns about VTE risk, consider:

• Progestin-only methods (pills, implant, IUD) - can be used without restriction in obese women 1
• Levonorgestrel IUD - no reduced efficacy, no increased VTE risk 1
• Copper IUD - non-hormonal option

Common Pitfalls to Avoid

1. Don't automatically exclude obese women from combined hormonal contraception - Guidelines support use in carefully selected patients under 35 without other risk factors 1

2. Don't assume reduced efficacy requires higher doses - Evidence doesn't support this, and higher estrogen doses increase VTE risk 1

3. Don't overlook that obesity alone increases pregnancy risk - Obese women have 4-fold higher risk of unintended pregnancy, making effective contraception crucial 1

4. Avoid transdermal patches in obese women - Body weight (not BMI) is associated with increased pregnancy risk with patches 1, 4

Monitoring Recommendations

• Reassess at 3-6 month intervals 6
• Monitor blood pressure
• Reinforce VTE warning signs
• Evaluate for any new cardiovascular risk factors that would change the risk-benefit calculation

The combination of norethindrone 1mg and estradiol 5mcg represents an ultra-low estrogen dose formulation, which may offer a favorable risk profile while maintaining efficacy 3.